Head to head
Biogen vs Eli Lilly and Co
Side-by-side on the measures that matter, with a plain-English read. Full detail: BIIB · LLY
BIIB
Biogen
222.15-0.33%
1-year price shape — +46% over the period
Quant Rating B · 80/100
vs
LLY
Eli Lilly and Co
1,188.72+2.70%
1-year price shape — +42% over the period
Quant Rating B · 79/100
1-year performance, rebased to 100
Eli Lilly and Co edges it on the scoreable measures. Eli Lilly and Co pays the highest dividend yield; Eli Lilly and Co earns the most per share.
| BIIB | LLY | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Drug Manufacturers - General |
| Last price | 222.15 | 1,188.72 |
| Change today | -0.33% | +2.70% |
| 1-year return | +45.9% | +41.8% |
| Market cap | $32.82B | $1.12T |
| 52-week range | 138.00 – 230.49 | 778.93 – 1,292.65 |
| Valuation | ||
| P/E (TTM) | 39.46 | 39.90 |
| P/E percentile, own 5-yr range | 100th | 6th |
| P/B | 1.74 | 33.03 |
| Dividend yield | 0.00% | 0.54% |
| Profitability & growth | ||
| EPS (TTM) | 8.79 | 22.95 |
| Net profit (TTM) | $1.30B | $21.60B |
| Revenue (TTM) | $10.03B | $79.67B |
| Revenue growth (YoY) | +3.4% | +47.7% |
| Gross margin | 74.0% | 83.4% |
| Operating margin | 19.3% | 49.7% |
| Net margin | 8.3% | 33.5% |
| Free cash flow (TTM) | $2.49B | $13.56B |
| Ownership & sentiment | ||
| Institutional ownership | 97.5% | 79.5% |
| Insider activity (12mo) | 35 buy / 15 sell | 37 buy / 13 sell |
| Short interest (% of float) | 3.9% | 0.8% |
| Analyst consensus | 65% buy / 31% hold / 4% sell (26) | 91% buy / 5% hold / 5% sell (22) |
| Analyst price target | $240 (+8%) | $1,381 (+16%) |
| StockVane view | ||
| StockVane Quant Rating | B (80) | B (79) |
| Company | ||
| Employees | 7,500 | 50,000 |
| Founded | 1978 | 1876 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.